COVID & Psychedelics: 3 Biotech Penny Stocks To Watch In August

“With coronavirus cases climbing in the U.S., this is likely going to be a clear focus for quite some time,” declares the author of today’s article in regards to the biotech sector. They proceed to highlight three biotech penny stocks to watch as August gets underway: two COVID-related plays as well as “one of the few listed penny stocks to have a foot in the emerging psychedelics industry.” For more, CLICK HERE.

“The Era Of Biotechs”

“The paralyzing viral outbreak that has swept the planet, costing trillions in output and gumming up the wheels of the global economy has also created a confluence of events so very favorable for biotechs that it will continue to push the sector higher up the golden arc,” declares the author of today’s article, which lays out the favorable macro environment for biotechs that is likely to persist beyond 2020 – and identifies a number of promising plays. For more, CLICK HERE.

Profit From The Coming Battery Boom With This Lithium Leader

If your phone or car uses a lithium-ion battery, the company highlighted in today’s article likely manufactured the lithium chemical used in that battery – and with the lithium-ion battery market expected to grow over 100% by 2025, this company’s stock may be set for a massive breakout. For the stock in question – which the author recommends as a buy based on its momentum and quality – CLICK HERE.

Harnessing The Power Of “Earnings Whispers” – And Other Strategies To Profit This (Unusual) Earnings Season

In this unusual earnings season that is getting underway, the author of today’s article observes that “Any stocks unfortunate enough to hiccup…will be severely punished. This will lead to devastating losses for those unlucky shareholders. However, the owners of stocks with positive surprises will be richly rewarded.” As such, he proceeds to outline three strategies to profit this earnings season – including harnessing the power of “earnings whispers”. For more, CLICK HERE.

3 “Strong Buy” Penny Stocks With Massive Upside Potential For Risk-Tolerant Investors

The market strategist cited in today’s article believes that the current stock market situation will get “resolved to the upside” – and for risk-tolerant investors who feel similarly, the author proceeds to highlight three compelling penny stocks with “Strong Buy” consensus ratings and massive upside potential (over 1,000% in one case). For these three penny stocks, CLICK HERE.

U.S. Traders May Be Accidentally Buying This Biotech Stock – But It May Be Worth Owning Anyways!

Shares of the biotech highlighted in today’s article have soared this year, but is this performance due to factors such as the COVID-19 drug the firm is developing and a planned spinoff of its diagnostic tool for predicting breast cancer – or is it due to traders being mistaken by the firm’s U.S. ticker symbol? For why U.S. traders may be accidentally buying shares of this biotech firm – and why the stock may be worth owning nonetheless – CLICK HERE.

What To Know About These Top Biotech Stocks To Watch

“July is a critical month for several leading biotech companies, and there’s a lot that investors need to know if they want to make a prudent decision about whether to invest,” advises the author of today’s article. He proceeds to examine three particular biotech stocks to watch this month and what investors need to know about each of them. For these three biotech stocks – including a gene therapy company whose “first major pipeline project is just months away from potentially getting regulatory approval” – CLICK HERE.

Options For An Uncertain Earnings Season

With second-quarter earnings season getting underway against what the author of today’s article acknowledges is “one of the most uncertain backdrops ever”, he advises that “It’s a good time to review some options strategies to manage risk in the age of coronavirus.” He proceeds to do just that, reviewing the key options strategies of long calls, vertical call spreads, bearish put spreads and covered calls. For more, CLICK HERE.

These 5 “Magic Formula” Biotech Stocks Are Guru Approved

On the heels of Novavax receiving $1.6 billion in federal aid for its COVID-19 vaccine candidate, the author of today’s article advises that “investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital” – and he highlights five top stocks in this regard that pass a “magic formula” screen and have the backing of investing gurus. For more, CLICK HERE.